Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

Global Education Group and i3 Health

Best Practices in Treatment Selection for Patients with Advanced Non-Small Cell Lung Cancer

Access Activity

Overview / Abstract:


An estimated 224,390 new cases of lung cancer occur in the United States annually, and 158,080 people die of the disease. Non-small cell lung cancer (NSCLC) represents nearly 83% of all lung cancers, with adenocarcinoma and squamous cell carcinoma each accounting for 30% to 50% of cases. Most patients with lung cancer are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of treatment. Although 70% to 80% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disease within 2 to 3 months of their final cycle. Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some patients. However, the 5-year survival rate for NSCLC remains only 17%, indicating a need for continued research on more effective approaches to tumor control.


Oncology physicians and other health care professionals involved in the treatment of NSCLC.


Upon completion of this activity, participants should be able to:

Assess the utility of tumor histology and molecular biomarker data in treatment planning for advanced NSCLC
Evaluate emerging and evolving efficacy and safety data on novel therapies for advanced NSCLC
Create individualized supportive care plans for patients with advanced NSCLC

There is no fee to participate in or claim CME credit for this activity.

Please note that Global Education Group and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and i3 Health. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Mark A. Socinski, MD has received grants/research support from Bristol-Myers Squibb, Clovis, Genentech, Lilly, Pfizer, and Synta, and has served on the speakers’ bureau for Bristol-Myers Squibb, Celgene, and Genentech.
Nathan A. Pennell, MD, PhD serves as a consultant/independent contractor for AstraZeneca and Boehringer Ingelheim.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Amanda Glazar, PhD: Nothing to disclose
Andrea Funk: Nothing to disclose
Laura Gilsdorf: Nothing to disclose
Melissa L. Cutrona: Nothing to disclose
Michael Bramwell: Nothing to disclose
Laurel Ranger: Nothing to disclose
Lodovico Balducci, MD: Has received honoraria from Amgen, TEVA, Johnson & Johnson, and Astellas
Jhanelle Gray, MD: Has received grants/research support from Array, AstraZeneca, Merck, and Trovagene, has served on the speakers’ bureau for Genentech, and has served as a consultant for AstraZeneca, Boehringer-Ingelheim, Celgene, Clovis, Genentech, and Lilly
John M. York, PharmD: Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and i3 Health do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Oct 31, 2017


Nurse Practitioner , Physician CME, Physician Assistant CME, Radiology / RAD Tech CE


Internet Point of Care (PoC), Monograph, Online

Credits / Hours




Presenters / Authors / Faculty

Mark A. Socinski, MD (Chairperson)
Executive Medical Director
Florida Hospital Cancer Institute

Nathan A. Pennell, MD, PhD
Director, Lung Cancer Medical Oncology Program
Cleveland Clinic Taussig Cancer Institute

Sponsors / Supporters / Grant Providers

Boehringer Ingelheim, Genentech, and Lilly

Keywords / Search Terms

i3 Health lung cancer, cancer, free cme, oncology, cancer care, supportive care, multidisciplinary team, adenocarcinoma, advanced stage, squamous cell carcinoma Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.